Use of bicyclol in treatment of chronic hepatitis B virus infection: a systematic review.
- Author:
Hui-fen WANG
1
;
Qiang LI
;
Pei LAN
Author Information
- Publication Type:Journal Article
- MeSH: Antiviral Agents; administration & dosage; adverse effects; Biphenyl Compounds; administration & dosage; adverse effects; Hepatitis B virus; drug effects; Hepatitis B, Chronic; drug therapy; Humans; Randomized Controlled Trials as Topic
- From: Chinese Journal of Experimental and Clinical Virology 2007;21(2):165-167
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of bicyclol for chronic hepatitis B.
METHODThe authors searched CBMDisk, CJFD (2000-2006), CJD-CD, PubMed (1966-2006) for randomized controlled trials (RCT) comparing bicyclol versus non-antiviral interventions, interferon alpha (IFN-a) and lamivudine for treatment of chronic hepatitis B. Two reviewers performed data extraction and quality assessment independently and discussed when there was different opinion. We analyzed the data with RevMan 4.2 software supplied by Cochrane Collabration.
RESULTSFourteen RCTs involving 1782 patients were included. ALT recovery rate of bicyclol group was 69.3 percent while that of the control group was 59.0 percent, the difference was statistical significant [RR 1.24, 95 percent CI (1.01, 1.52), P=0.04]. Loss of HBeAg in the bicyclol group (22.1 percent) was higher than that of the control group (13.5 percent) [RR 1.65, 95 percent CI (1.32, 2.06), P<0.00001]. No serious adverse events were reported.
CONCLUSIONBicyclol might be beneficial to recovery of liver function and loss of serum HBV marker. However, more high quality clinical trials are needed for confirmation.
